Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 °C whole body hyperthermia in patients with refractory sarcoma
1996; Elsevier BV; Volume: 32; Issue: 5 Linguagem: Inglês
10.1016/0959-8049(95)00622-2
ISSN1879-0852
AutoresG. Wiedemann, H. Ian Robins, Sven Gutsche, M. Mentzel, Michael Deeken, Dörthe M. Katschinski, S. Eleftheriadis, R. Crahe, Christoph Weiss, Barry E. Storer, Thomas Wagner,
Tópico(s)Ultrasound Imaging and Elastography
ResumoTwo earlier studies resulted in the design of a phase II trial of 41.8 °C (x 60 min) extracorporeal whole body hyperthermia (WBH) with ICE, i.e. ifosfamide (5 g/m2), carboplatin (300 mg/m2) and etoposide given with WBH, as well as, day 2 and 3 post-WBH (100 mg/m2) for adult patients with refractory sarcoma. 12 patients entered this trial; all were evaluable. 8 patients had a history of prior chemotherapy associated with disease progression. Following WBH/ICE, 7 partial remissions were observed (58%); 3 patients experienced disease stabilisation; the aforementioned 10 patients each received four cycles of therapy. 2 patients exhibited progressive disease. Episodes of WHO graded (grade 3; grade 4) toxicity observed included: anaemia (2;2); leucopenia (5;7); thrombocytopenia (1;6); renal (0;1). Other toxicities (grade 1 and 2) included: anasarca, diarrhoea, ventricular arrhythmias, pressure sores and perioral herpes simplex.
Referência(s)